Skip to main content
Premium Trial:

Request an Annual Quote

DiaGenic, Pfizer Sign Deal for Alzheimer's Biomarker Discovery

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Norwegian biotech DiaGenic said it will use its gene expression technology to identify biomarkers of early-stage Alzheimer's disease for Pfizer, under a deal announced today by DiaGenic.

The firms will conduct a study, expected to begin this month, to compare longitudinal changes in blood-based gene expression patterns in patients with stable mild cognitive impairment, progressive MCI, and Alzheimer's disease. They hope to identify gene expression patterns in patients who progress from MCI to Alzheimer's disease and with different stages of the disease.

Pfizer will receive a non-exclusive, worldwide license for use of DiaGenic's MCI test and Alzheimer's test in its R&D development programs.

Additional terms of the deal were not disclosed.

In a statement, Erik Christensen, CEO of Oslo, Norway-based DiaGenic, said the deal "is the first result of DiaGenic's refocused strategy on teaming up with large pharmaceutical companies to deliver new diagnostic tools."

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.